UY37757A - Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante - Google Patents

Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante

Info

Publication number
UY37757A
UY37757A UY0001037757A UY37757A UY37757A UY 37757 A UY37757 A UY 37757A UY 0001037757 A UY0001037757 A UY 0001037757A UY 37757 A UY37757 A UY 37757A UY 37757 A UY37757 A UY 37757A
Authority
UY
Uruguay
Prior art keywords
extracellular domain
kits
procedures
compositions
recombinant human
Prior art date
Application number
UY0001037757A
Other languages
English (en)
Spanish (es)
Inventor
Jody Berry
Matteo Binda
Elizabeth Booth
Vincenzo Favaloro
John A Hall
Peter Schwind
Original Assignee
Grifols Diagnostic Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Diagnostic Solutions Inc filed Critical Grifols Diagnostic Solutions Inc
Publication of UY37757A publication Critical patent/UY37757A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UY0001037757A 2017-08-10 2018-06-01 Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante UY37757A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762543788P 2017-08-10 2017-08-10

Publications (1)

Publication Number Publication Date
UY37757A true UY37757A (es) 2018-11-30

Family

ID=62846219

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037757A UY37757A (es) 2017-08-10 2018-06-01 Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante

Country Status (18)

Country Link
US (3) US11708418B2 (enExample)
EP (3) EP3587445B1 (enExample)
JP (3) JP6833851B2 (enExample)
KR (2) KR20240015159A (enExample)
CN (2) CN117820498A (enExample)
AR (1) AR112357A1 (enExample)
AU (2) AU2018313028B2 (enExample)
BR (1) BR112020002636A2 (enExample)
CA (1) CA3070789A1 (enExample)
EA (1) EA202090265A1 (enExample)
ES (2) ES2973864T3 (enExample)
HU (1) HUE065510T2 (enExample)
MX (3) MX2020001489A (enExample)
PL (1) PL3587445T3 (enExample)
PT (1) PT3587445T (enExample)
TW (1) TW201910349A (enExample)
UY (1) UY37757A (enExample)
WO (1) WO2019030581A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR112357A1 (es) * 2017-08-10 2019-10-23 Grifols Diagnostic Solutions Inc Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano
TW202000692A (zh) * 2018-02-20 2020-01-01 美商格里佛診斷方法股份有限公司 包含GpIbα的多肽和組合物、編碼該多肽的核酸及包含該多肽或該核酸的細胞
CN112048019B (zh) * 2019-06-06 2023-05-09 鲁南制药集团股份有限公司 抗人cd47单克隆抗体
AU2021338773A1 (en) * 2020-09-10 2023-05-25 Casi Pharmaceuticals, Inc. Methods of blood screening
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114917413B (zh) * 2022-06-14 2023-04-28 健诺维(成都)生物科技有限公司 一种负载重组多肽的羊膜及其制备方法
WO2024172419A1 (ko) * 2023-02-16 2024-08-22 주식회사 디엔티 Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6506551B1 (en) * 1999-10-08 2003-01-14 North Shore - Long Island Jewish Research Institute CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
AU2001273121A1 (en) * 2000-06-30 2002-01-14 Pharmacia And Upjohn Company Recombinant staphylococcus aureus peptide deformylase
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
SI2511297T1 (sl) * 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
EP3753576A1 (en) * 2006-09-26 2020-12-23 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN103897063B (zh) * 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
EP2388270A3 (en) * 2007-10-11 2012-04-25 The Hospital For Sick Children Modulation of SIRPa - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
WO2010037837A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
SG194399A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
WO2010083253A2 (en) * 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
PL3053932T3 (pl) * 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
US20130029358A1 (en) * 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
SG188328A1 (en) * 2010-09-03 2013-04-30 Stem Centrx Inc Novel modulators and methods of use
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
EP2812443B1 (en) * 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
ES2857900T3 (es) * 2012-04-27 2021-09-29 Novo Nordisk As Proteínas de unión a antígeno de ligando CD30 humano
SG11201408646VA (en) * 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
US9599606B2 (en) * 2014-06-10 2017-03-21 The Board Of Regents Of The University Of Texas System ADP-ribose detection reagents
KR102252119B1 (ko) * 2014-06-18 2021-05-17 앨버트 아인슈타인 컬리지 오브 메디신 Syntac 폴리펩티드 및 이의 용도
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
WO2016081423A1 (en) * 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
EP3263599A4 (en) * 2015-02-16 2018-12-19 Pharma Foods International Co., Ltd. Anti-cancer agent and antimetastatic agent using fstl1, and concomitant drug for same
US9580477B2 (en) * 2015-03-16 2017-02-28 The Catholic University Of America Approach to produce HIV-1 GP140 envelope protein trimers
SI3274370T1 (sl) * 2015-03-23 2020-02-28 Bayer Pharma Aktiengesellschaft Protitelesa proti CEACAM6 in njihova uporaba
CA2989993A1 (en) * 2015-09-08 2017-03-16 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
JP2019503167A (ja) * 2015-11-10 2019-02-07 ユニバーシティ・メディカル・センター・ハンブルク−エッペンドルフUniversity Medical Center Hamburg − Eppendorf Cd38に対する抗原結合性ポリペプチド
AR112357A1 (es) * 2017-08-10 2019-10-23 Grifols Diagnostic Solutions Inc Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano

Also Published As

Publication number Publication date
EP4296680A2 (en) 2023-12-27
ES2973864T3 (es) 2024-06-24
US20210198376A1 (en) 2021-07-01
JP2021088567A (ja) 2021-06-10
KR20240015159A (ko) 2024-02-02
AU2018313028A1 (en) 2020-02-20
KR20200035194A (ko) 2020-04-02
CA3070789A1 (en) 2019-02-14
MX2024005669A (es) 2024-05-30
EA202090265A1 (ru) 2020-06-05
WO2019030581A1 (en) 2019-02-14
HUE065510T2 (hu) 2024-05-28
PT3587445T (pt) 2024-03-14
JP6833851B2 (ja) 2021-02-24
AU2018313028B2 (en) 2023-05-25
BR112020002636A2 (pt) 2020-07-28
MX2024008109A (es) 2024-07-19
CN109790210A (zh) 2019-05-21
CN109790210B (zh) 2024-03-26
US11708418B2 (en) 2023-07-25
KR102631281B1 (ko) 2024-01-30
CN117820498A (zh) 2024-04-05
US20240132616A1 (en) 2024-04-25
US20240228651A9 (en) 2024-07-11
JP2019527533A (ja) 2019-10-03
ES2911243T3 (es) 2022-05-18
EP3464343A1 (en) 2019-04-10
EP3587445B1 (en) 2023-12-13
AU2023204121A1 (en) 2023-07-20
MX2020001489A (es) 2020-03-20
US20240092929A1 (en) 2024-03-21
EP3464343B1 (en) 2022-03-23
JP7289328B2 (ja) 2023-06-09
EP4296680A3 (en) 2024-03-20
EP3587445A1 (en) 2020-01-01
PL3587445T3 (pl) 2024-04-29
TW201910349A (zh) 2019-03-16
AR112357A1 (es) 2019-10-23
JP2023041802A (ja) 2023-03-24

Similar Documents

Publication Publication Date Title
UY37757A (es) Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CR20200467A (es) Agentes anticuerpos anti-cd25
CR20230169A (es) ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485)
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
DOP2016000282A (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
EA201890383A8 (ru) Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3)
CL2008003561A1 (es) Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias.
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
MX2020005562A (es) Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1.
EA201891196A1 (ru) Cgrp-антитела и их применение
AR110680A1 (es) Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
BR112018075901A2 (pt) anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20241010